Related Experiment Video
Updated: Jul 6, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a
Julius L Katzmann1, Paulina E Stürzebecher2, Silvia Kruppert3
1Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany. julius.katzmann@medizin.uni-leipzig.de.
Abstract:
The inability to tolerate sufficient doses of statins, statin intolerance (SI), contributes to the non-achievement of guideline-recommended low-density lipoprotein cholesterol (LDL-C) treatment targets. Patients with SI require alternative lipid-lowering therapies (LLT). We conducted a simulation study on LDL-C target achievement with oral LLT (ezetimibe, bempedoic acid) in patients with SI, using representative data of 2.06 million German outpatients. SI was defined using literature-informed definitions based on electronic medical records (EMR). Among n = 130,778 patients with hypercholesterolaemia, available LDL-C measurement, and high or very-high cardiovascular risk, 8.6% met the definition of SI. Among patients with SI, 7.7% achieved the LDL-C target at baseline. After simulation of the stepwise addition of treatment with ezetimibe and bempedoic acid, 22.6 and 52.0% achieved the LDL-C target, respectively. The median achieved LDL-C was 80 and 62 mg/dL, the corresponding reductions from baseline were 20.0 and 38.0%, respectively. A higher proportion of patients classified as high risk achieved the target compared to those at very-high risk (58.1 vs. 49.9%). In conclusion, in patients with increased cardiovascular risk meeting the definition of SI based on EMR, combination LLT with ezetimibe and bempedoic acid has the potential to substantially increase the proportion of patients achieving clinically relevant LDL-C reductions.
Insights
Statin intolerance (SI) hinders LDL-C target achievement. Alternative therapies like ezetimibe and bempedoic acid significantly increase the likelihood of reaching lipid goals in high-risk patients with SI.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Statin intolerance (SI) is a significant barrier to achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets.
- Patients experiencing SI necessitate alternative lipid-lowering therapies (LLT) to manage hypercholesterolemia and reduce cardiovascular risk.
- Electronic medical records (EMR) provide valuable data for defining and analyzing patient populations with SI.
Purpose of the Study:
- To simulate LDL-C target achievement using oral LLT (ezetimibe, bempedoic acid) in patients with SI.
- To assess the effectiveness of ezetimibe and bempedoic acid as monotherapies and in combination for SI patients.
- To evaluate the proportion of high and very-high cardiovascular risk patients achieving LDL-C targets with alternative LLT.
Main Methods:
- A simulation study utilizing representative data from 2.06 million German outpatients.
- SI was defined using literature-informed criteria applied to EMR data.
- LDL-C target achievement was simulated with stepwise addition of ezetimibe and bempedoic acid in patients with hypercholesterolemia and high/very-high cardiovascular risk.
Main Results:
- 8.6% of 130,778 eligible patients met the SI definition; only 7.7% achieved LDL-C targets at baseline.
- Simulated treatment with ezetimibe and bempedoic acid increased LDL-C target achievement to 22.6% and 52.0%, respectively.
- Combination therapy with ezetimibe and bempedoic acid demonstrated substantial potential for increasing LDL-C reductions in SI patients.
Conclusions:
- Oral LLT, including ezetimibe and bempedoic acid, can significantly improve LDL-C target attainment in patients with SI and high cardiovascular risk.
- The combination of ezetimibe and bempedoic acid offers a promising strategy for managing hypercholesterolemia in patients intolerant to statins.
- These findings highlight the importance of alternative LLT in achieving cardiovascular risk reduction goals for patients with SI.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...